OSLO, Norway, Sept. 20, 2023 /PRNewswire/ -- Photocure ASA (OSE:PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE:688176) has communicated today that the multinational Cevira® Phase III clinical trial has been completed and successfully met its primary endpoint. Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.
Read more at prnewswire.comPhotocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
